

Claims

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of ~~treating a human or animal having undesirable~~ inhibiting endothelial cell proliferation in a human or animal comprising,
administering to the human or animal a sufficient amount of a composition comprising a tissue factor pathway inhibitor C-terminal peptide to inhibit the undesirable endothelial cell proliferation.
2. (Currently Amended) The method of Claim 1 wherein the ~~undesirable~~ endothelial cell proliferation is an angiogenesis-related disease.
3. (Original) The method of Claim 2, wherein the angiogenesis-related disease is a disease selected from the group consisting of hemangioma, solid tumors, leukemia, metastasis, telangiectasia psoriasis scleroderma, pyogenic granuloma, myocardial angiogenesis, plaque neovascularization, coronary collaterals, ischemic limb angiogenesis, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, and placentation.
4. (Original) The method of Claim 1 wherein administration of the composition inhibits angiogenesis.

5. (Original) The method of Claim 1 wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO: 5, a homolog thereof, or an anti-proliferative fragment thereof.

6. (Original) The method of Claim 5 wherein the anti-proliferative fragment is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.

7. (Withdrawn) The method of Claim 5 wherein the anti-proliferative fragment consists of SEQ ID NO: 3.

8. (Original) The method of Claim 1 wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO. 6, a homolog thereof, or an anti-proliferative fragment thereof.

9. (Withdrawn) The method of Claim 8 wherein the anti-proliferative fragment consists of SEQ ID NO: 4.

10. (Original) The method of Claim 1 wherein the composition further comprises a pharmaceutically acceptable excipient, carrier or sustained-release matrix.

11. (Currently Amended) A method for treating an angiogenesis-related disease comprising,

administering to a human or animal a sufficient amount of a composition comprising a tissue factor pathway inhibitor C-terminal peptide to inhibit the undesirable endothelial cell proliferation.

12. (Original) The method of Claim 11, wherein the angiogenesis-related disease is a disease selected from the group consisting of hemangioma, solid tumors, leukemia, metastasis, telangiectasia psoriasis scleroderma, pyogenic granuloma, myocardial angiogenesis, plaque neovascularization, coronary collaterals, ischemic limb angiogenesis, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, and placentation.

13. (Original) The method of Claim 11 wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO. 5, a homolog thereof, or an anti-proliferative fragment thereof.

14. (Original) The method of Claim 13 wherein the anti-proliferative fragment is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.

15. (Withdrawn) The method of Claim 14 wherein the anti-proliferative fragment consists of SEQ ID NO: 3.

16. (Withdrawn) The method of Claim 11 wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO. 6, a homolog thereof, or an anti-proliferative fragment thereof.

17. (Original) The method of Claim ~~16~~ 11 ~~wherein the anti-proliferative fragment consists of SEQ ID NO: 4~~ wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO. 4, a homolog thereof, or an anti-proliferative fragment thereof.

Appl. No. 10/086,176

Amendment and Response dated September 17, 2004

Reply to Office Action of December 2, 2003

Filed in Conjunction with Petition to Revive

18. (Original) The method of Claim 11 wherein the composition further comprises a pharmaceutically acceptable excipient, carrier or sustained-release matrix.